insights_auto
Zašto je 2X1 skočio 2,86%?
Istražite detaljnijechevron_right
2X1:ETR
Abivax SA
79,00 €
arrow_upward
+2,86%(+2,20) 1D
9. lis, 17:35:37 GMT+2 · EUR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za 2X1...
Otvori
78,95 €
Najviša
80,40 €
Najniža
78,95 €
Trž. kap.
6,81 mlr.
Prosj. kol.
1,81 tis.
Količina
189,00
52-tjed. najviša
137,40 €
52-tjed. najniža
60,85 €
EPS
−5,20 €
Broj djelatnika
98
Otvori
78,95 €
Najviša
80,40 €
Najniža
78,95 €
Trž. kap.
6,81 mlr.
Prosj. kol.
1,81 tis.
Količina
189,00
52-tjed. najviša
137,40 €
52-tjed. najniža
60,85 €
EPS
−5,20 €
Broj djelatnika
98
Vijesti
Iz web-izvora i od partnera za vijesti
MarketBeat
·
prije 20 sati
Vilga Financial Planning LLC Acquires 22,000 Shares of Abivax SA Sponsored ADR $ABVX
TradingView
·
prije 1 dan
Abivax SA Stock 12‑Month Price Target Cut to $159.06, Implies 79% Upside
Ideal Investisseur
·
prije 1 dan
Abivax: stock plunges 1.5% and deepens its fall to 39% in three months
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA – informacije
Glavni izvršni direktorMarc de Garidel | Hartmut J. Ehrlich
Zaposlenici98
Osnovano4. pro 2013.
Sjedište-
Sektor-
Web-lokacijaabivax.com